Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896

RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Scleroderma, Diffuse

Interventions: rapcabtagene autoleucel, rituximab

Countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Czechia, Denmark

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

Eligibility overview

Sex: ALL

Age: 18 Years to 70 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

1. Participant must fulfill the 2013 American College of Rheumatology/ European League Against Rheumatism classification criteria for systemic sclerosis and meet the diffuse cutaneous SSc (dcSSc) subset classification according to LeRoy.
2. Disease onset from the first non-Raynaud symptoms attributable to SSc (e.g., puffy hands, scleroderma, digital ulcers, arthralgia, dyspnea) within 7 years prior to the Screening visit.
3. Severe, progressive systemic sclerosis disease defined by at least one of the following:

   * Progressive systemic sclerosis-associated interstitial lung disease
   * Severe, progressive systemic sclerosis skin disease
   * Clinically significant systemic sclerosis-associated cardiac involvement at Screening
4. All recommended vaccinations received according to institutional, local or global guidelines for immuno-compromised patients.

Exclusion Criteria:

1. Any condition during Screening that could prevent a complete washout of medications as required per protocol or could otherwise make the participant ineligible for anti-CD19 CAR-T therapy and further participation in the study, as judged by the Investigator.
2. Participants with history of hypersensitivity to excipients in rapcabtagene autoleucel or to rituximab.
3. Any participant for whom treatment with rituximab is clinically inappropriate in the opinion of the investigator.
4. Any medical conditions that are not related to SSc that, in the opinion of the Investigator, would jeopardize the ability of the participant to tolerate lymphodepletion and anti-CD19 CAR-T cell therapy.
5. Rheumatic disease other than dcSSc, (except secondary Sjogren's syndrome or scleroderma myopathy),including limited cutaneous systemic sclerosis (lcSSc) or sine scleroderma at Screening.
6. Participants with pre-existing pulmonary hypertension.
7. Significant renal pathology at Screening.
8. Participants with uncontrolled stage II hypertension at Screening.
9. Vaccination with live attenuated vaccines within 6 weeks prior to randomization.

Other protocol-defined inclusion/exclusion criteria may apply.
Locations (92)
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • San Francisco, California, United States
  • San Pablo, California, United States
  • Zephyrhills, Florida, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Sioux Falls, South Dakota, United States
  • Salt Lake City, Utah, United States
  • CABA, Argentina
  • Córdoba, Argentina
  • Camperdown, New South Wales, Australia
  • Darlinghurst, New South Wales, Australia
  • Graz, Austria
  • Vienna, Austria
  • Ghent, Belgium
  • Salvador, Estado de Bahia, Brazil
  • Curitiba, Paraná, Brazil
  • Barretos, São Paulo, Brazil
  • São Paulo, São Paulo, Brazil
  • São Paulo, São Paulo, Brazil
  • Olomouc, Czechia
  • Prague, Czechia
  • Aarhus N, Denmark
  • Bordeaux, France
  • + 62 more on CT.gov